At present, PD-1/PD-L1 expression levels, and tumor mutation burden have become the main detection biomarkers before clinical immunotherapy, with the aim of screening patients with NSCLC who are suitable for individualized immunotherapy. This evidence concerns the gene CD274 and neoplasm.